Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Chemicals & Drugs
>
Organic Chemical
>
Albuterol
Albuterol
Albuterol is a short-acting beta2-adrenergic agonist medication used to treat and prevent bronchospasm in patients with reversible obstructive airway disease, such as asthma.
It works by relaxing and opening the airways, allowing for easier breathing.
Albuterol is commonly administered via inhalation and is available in various formulations, including metered-dose inhalers, nebulizer solutions, and oral tablets.
Careful dosing and monitoring are important, as Albuterol can have stimulant effects and may interact with certain medications.
Reserarch on Albuterol's efficacy, safety, and optimial use is an active area of study.
It works by relaxing and opening the airways, allowing for easier breathing.
Albuterol is commonly administered via inhalation and is available in various formulations, including metered-dose inhalers, nebulizer solutions, and oral tablets.
Careful dosing and monitoring are important, as Albuterol can have stimulant effects and may interact with certain medications.
Reserarch on Albuterol's efficacy, safety, and optimial use is an active area of study.
Most cited protocols related to «Albuterol»
Albuterol
Ankle
BLOOD
Blood Pressure
Eligibility Determination
Glucose
Glucose Tolerance Test
Healthy Volunteers
Hispanic or Latino
Infantile Neuroaxonal Dystrophy
Lung
Periodontium
Physical Examination
Safety
Snacks
Woman
Adrenal Cortex Hormones
Albuterol
Allergens
Asthma
BLOOD
Child
Clinical Trials Data Monitoring Committees
Fluticasone
Methacholine
Minority Groups
Oxide, Nitric
Pharmaceutical Preparations
Physical Examination
Signs, Vital
Smokers, Tobacco
Spirometry
Sputum
Therapeutics
Woman
We collected demographic data, pharmacy records and the primary ICD-9 code for all outpatient and inpatient visits during the exact calendar date one year pre- and one year post the index date utilizing the VA computerized medical record system.
Patients with any of the following primary ICD-9 codes were considered to have a COPD-related visit: 491.xx - chronic bronchitis, 492.xx - emphysema, 493.2 - chronic obstructive asthma, 496.xx - chronic airway obstruction, not elsewhere classified. We did not include 490 - Bronchitis, not specified as acute or chronic in our administrative definition of COPD because the definition itself lacks specificity which increases the concern about misclassification [23 (link),24 (link)]. Outpatient primary and secondary ICD-9 codes were those recorded during a patient encounter in any outpatient clinic while inpatient primary ICD-9 codes were those recorded during an admission to the hospital. ICD-9 codes generated during visits to the pulmonary function laboratory were not considered in this analysis. Although secondary ICD-9 codes were considered for defining a COPD-related visit these were uncommonly (<7% of visits) coded by providers. Comorbid conditions relevant to patients with COPD were determined using ICD-9 codes for all previous outpatient visits in the one year period prior to the index date. These included a diagnosis of lung cancer (162.x, 163.x), acute coronary syndrome (410.xx, 411.xx), congestive heart failure (398.91,415.xx, 416.xx,425.x, 428.x), diabetes (250.x), hypertension (401.xx-405.xx), atrial fibrillation (427.xx), depression (311, 300.4, 296.2x, 296.3x), and schizophrenia (295.xx).
Smoking was assessed at the time of spirometry; patients were classified as never/former or current based upon self report. We determined the total number of metered dose inhaler (MDI) canisters prescribed over the two year period to each patient for both albuterol and ipratropium bromide (categorized as: albuterol - 0, 1-5, 6+ MDI; ipratropium - 0, 1-2, 3+) using the Veterans Integrated Service Network (VISN) data warehouse. The VISN data warehouse contains the complete pharmacy records for patients who filled prescriptions within the VISN region. These data include the drug name, class, prescription identification number, prescription fill dates (primary and refills), number of allowable refills, date of next allowable refill, amount dispensed, day supply, unit price of the medication and directions for use. Nebulized medications were not included in the calculation of these totals. Tiotropium was not included in our analysis as it was adopted slowly in the VA because of formulary restriction.
Patients with any of the following primary ICD-9 codes were considered to have a COPD-related visit: 491.xx - chronic bronchitis, 492.xx - emphysema, 493.2 - chronic obstructive asthma, 496.xx - chronic airway obstruction, not elsewhere classified. We did not include 490 - Bronchitis, not specified as acute or chronic in our administrative definition of COPD because the definition itself lacks specificity which increases the concern about misclassification [23 (link),24 (link)]. Outpatient primary and secondary ICD-9 codes were those recorded during a patient encounter in any outpatient clinic while inpatient primary ICD-9 codes were those recorded during an admission to the hospital. ICD-9 codes generated during visits to the pulmonary function laboratory were not considered in this analysis. Although secondary ICD-9 codes were considered for defining a COPD-related visit these were uncommonly (<7% of visits) coded by providers. Comorbid conditions relevant to patients with COPD were determined using ICD-9 codes for all previous outpatient visits in the one year period prior to the index date. These included a diagnosis of lung cancer (162.x, 163.x), acute coronary syndrome (410.xx, 411.xx), congestive heart failure (398.91,415.xx, 416.xx,425.x, 428.x), diabetes (250.x), hypertension (401.xx-405.xx), atrial fibrillation (427.xx), depression (311, 300.4, 296.2x, 296.3x), and schizophrenia (295.xx).
Smoking was assessed at the time of spirometry; patients were classified as never/former or current based upon self report. We determined the total number of metered dose inhaler (MDI) canisters prescribed over the two year period to each patient for both albuterol and ipratropium bromide (categorized as: albuterol - 0, 1-5, 6+ MDI; ipratropium - 0, 1-2, 3+) using the Veterans Integrated Service Network (VISN) data warehouse. The VISN data warehouse contains the complete pharmacy records for patients who filled prescriptions within the VISN region. These data include the drug name, class, prescription identification number, prescription fill dates (primary and refills), number of allowable refills, date of next allowable refill, amount dispensed, day supply, unit price of the medication and directions for use. Nebulized medications were not included in the calculation of these totals. Tiotropium was not included in our analysis as it was adopted slowly in the VA because of formulary restriction.
Full text: Click here
Acute Coronary Syndrome
Albuterol
Asthma
Atrial Fibrillation
Bronchitis
Bronchitis, Chronic
Chronic Obstructive Airway Disease
Congestive Heart Failure
Diabetes Mellitus
Diagnosis
Emphysema
High Blood Pressures
Inpatient
Ipratropium
Ipratropium Bromide
Lung
Lung Cancer
Metered Dose Inhaler
Outpatients
Patients
Pharmaceutical Preparations
Schizophrenia
Spirometry
Tiotropium
Veterans
Adrenal Cortex Hormones
Adult
African American
Albuterol
Allergens
Asthma
Bronchodilator Agents
Child
Cockroaches
Dermatophagoides pteronyssinus antigen p 1
Environmental Exposure
Ergocalciferol
Health Insurance
Hospitalization
Households
Hypersensitivity
Index, Body Mass
LAMP3 protein, human
Negroid Races
Nicotiana tabacum
Parent
Plasma
Premature Birth
Pyroglyphidae
Respiratory Physiology
Smoke
Sperm Injections, Intracytoplasmic
Uterus
Statistical analysis was carried out using the “Statistical Package for Social Sciences (SPSS) for windows” software, version 20. The appropriate sample size and power calculations were carried out using Quanto software package version 1.2.4 (University of Southern California; http://biostats.usc.edu/software ). Categorical variables were compared using chi-square (χ2) test, while the Studenť s t test and one way analysis of variance (ANOVA) were used to compare continuous variables between two groups, and for more than two groups, respectively, in case the data distribution was concordant with normal distribution (Shapiro-Wilk test) and after checking variance homogeneity (Levene test), followed by appropriate multiple comparison test (post-hoc Newman-Keuls test). If the data did not meet the criteria mentioned above, the non-parametric Mann-Whitney (MW) test for comparing two groups and Kruskal-Wallis (KW) test for comparing more than two groups followed by Dunn's test, were applied. The allelic frequencies were calculated by direct counting the alleles. Genotype distributions in patients and controls were evaluated for departure from Hardy–Weinberg equilibrium (HWE) by the Online Encyclopedia for Genetic Epidemiology (OEGE) software (http://www.oege.org/software/hwe-mr-calc.shtml ). The goodness of fit for the Chi square test was applied to compare the expected versus observed distribution of genotypes. Odds ratios (OR) with a 95% confidence interval (CI) were calculated for the following genetic models; allelic model (T versus C), homozygote comparison (TT versus CC), heterozygote comparison (CT versus CC), dominant model (TT+CT versus CC), and recessive model (TT versus CT+CC). Binary logistic regression analysis was performed to adjust potential confounders (obesity, smoking, family history of COPD) with the polymorphism as an independent variable. A two-tailed P-value of 0.05 was considered statistically significant. The Brinkman smoking index was calculated as the number of cigarettes smoked per day × number of years. Response to salbutamol was expressed in three ways: [1 (link)] absolute change in forced expiratory volume in first second FEV1 [BDRABS = postbronchodilator FEV1 − prebronchodilator FEV1], [2 (link)] change in FEV1 as a percent of baseline FEV1 [BDRBASE = (postbronchodilator FEV1 − prebronchodilator FEV1) / (prebronchodilator FEV1)× 100], and [3 (link)] change in FEV1 as a percent of predicted FEV1 [BDRPRED = (postbronchodilator FEV1 − prebronchodilator FEV1) / (predicted FEV1)× 100] [45 (link), 46 (link)].
Full text: Click here
Albuterol
Alleles
Chronic Obstructive Airway Disease
Genetic Polymorphism
Genotype
Heterozygote
Homozygote
Obesity
Patients
Volumes, Forced Expiratory
Most recents protocols related to «Albuterol»
All participants were aged 18 years or older. Asthma was diagnosed based on Global Initiative for Asthma (GINA) criteria (29 ): (I) history of variable respiratory symptoms; (II) variable expiratory airflow limitation, e.g., increase in forced expiratory volume in the first second (FEV1) of >12% and >200 mL after salbutamol (albuterol) inhalation; (III) effective of medications for asthma. COPD was diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (30 (link)): FEV1 to forced vital capacity (FVC) of <0.7 after salbutamol (albuterol) inhalation. COPD patients with asthma were excluded from our study.
Healthy controls were eligible for this study according to the following criteria: (I) without a diagnosis of COPD, asthma, or any other respiratory diseases; (II) no history of respiratory allergic diseases or any other respiratory symptom, like wheezing, shortness of breath; (III) no use of medications for asthma and COPD. Spirometry without bronchodilation was performed for all healthy controls.
Individuals were excluded from the study if they (I) were diagnosed with asthma-COPD overlap syndrome; (II) had a suspected acute inflammatory or infectious disease; (III) had a history of stroke or acute coronary syndrome; (IV) experienced venous thromboembolism; (V) received anticoagulant therapy; (VI) were diagnosed with cancer within the last 5 years; (VII) were pregnant or under hormone-replacement therapy.
Healthy controls were eligible for this study according to the following criteria: (I) without a diagnosis of COPD, asthma, or any other respiratory diseases; (II) no history of respiratory allergic diseases or any other respiratory symptom, like wheezing, shortness of breath; (III) no use of medications for asthma and COPD. Spirometry without bronchodilation was performed for all healthy controls.
Individuals were excluded from the study if they (I) were diagnosed with asthma-COPD overlap syndrome; (II) had a suspected acute inflammatory or infectious disease; (III) had a history of stroke or acute coronary syndrome; (IV) experienced venous thromboembolism; (V) received anticoagulant therapy; (VI) were diagnosed with cancer within the last 5 years; (VII) were pregnant or under hormone-replacement therapy.
Acute Coronary Syndrome
Albuterol
Anticoagulants
Asthma
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
Cerebrovascular Accident
Chronic Obstructive Airway Disease
Communicable Diseases
Dyspnea
Expiratory Airflow
Forced Vital Capacity
Gold
Hypersensitivity
Inflammation
Inhalation
Malignant Neoplasms
Patients
Pharmaceutical Preparations
Respiration Disorders
Respiratory Rate
Signs and Symptoms, Respiratory
Spirometry
Therapeutics
Therapy, Hormone Replacement
Venous Thromboembolism
Volumes, Forced Expiratory
This retrospective study was conducted at the University of Kansas Medical Center (Westwood, KS, USA) in collaboration with the United States Myeloma Innovations Research Collaborative (USMIRC). The study covered the period between January 2015 and June 2022 and received approval from the University of Kansas Institutional Review Board and conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Subjects with a diagnosis of RRMM who received DPd in the second or subsequent lines of therapy were included. We reviewed electronic health records to extract relevant patient data including age, gender, race, MM type and stage, cytogenetics, and treatment lines including auto-HSCT. In addition, we obtained the hematological laboratory parameters of patients over the course of their DPd treatments, as well as any treatment-related adverse events described in their medical records.
The standard-of-care DPd regimen specified daratumumab administered weekly 16 mg/kg intravenously or 1,800 mg subcutaneously with hyaluronidase for the first 8 weeks, every 2 weeks from weeks 9 to 24, and then monthly until discontinuation of treatment due to disease progression or unacceptable toxicity. Pomalidomide dosage was 4 mg orally every day for 21 days as part of a 28-day cycle. Dexamethasone dosage was 20 mg weekly for patients aged 75 and older and 40 mg weekly for patients younger than 75. Antithrombotic and antiviral prophylaxis was carried out as recommended in clinical trials and practice guidelines. Patients were premedicated with glucocorticoids, acetaminophen, and diphenhydramine to prevent infusion reactions and, if required, with albuterol and montelukast in cases of underlying lung disease. Renal, hepatic, and hematological parameters were monitored during DPd therapy. Pomalidomide dosage was adjusted in line with the package insert if cytopenia occurred. Dose reduction was from 4 mg to 3 mg, then to 2 mg, and then to 1 mg; if the patient could not tolerate the lowest dose, pomalidomide was permanently discontinued. For daratumumab, there is no dose reduction, but delay in treatment until resolution of cytopenia and or infection.
Response to therapy was assessed using the International Myeloma Working Group (IMWG) criteria [12 (link)]. Grading of hematological and non-hematological adverse events was determined following the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [13 ]. Survival outcomes such as PFS and overall survival (OS) were estimated by means of Kaplan-Meier curves using log-rank testing.
The standard-of-care DPd regimen specified daratumumab administered weekly 16 mg/kg intravenously or 1,800 mg subcutaneously with hyaluronidase for the first 8 weeks, every 2 weeks from weeks 9 to 24, and then monthly until discontinuation of treatment due to disease progression or unacceptable toxicity. Pomalidomide dosage was 4 mg orally every day for 21 days as part of a 28-day cycle. Dexamethasone dosage was 20 mg weekly for patients aged 75 and older and 40 mg weekly for patients younger than 75. Antithrombotic and antiviral prophylaxis was carried out as recommended in clinical trials and practice guidelines. Patients were premedicated with glucocorticoids, acetaminophen, and diphenhydramine to prevent infusion reactions and, if required, with albuterol and montelukast in cases of underlying lung disease. Renal, hepatic, and hematological parameters were monitored during DPd therapy. Pomalidomide dosage was adjusted in line with the package insert if cytopenia occurred. Dose reduction was from 4 mg to 3 mg, then to 2 mg, and then to 1 mg; if the patient could not tolerate the lowest dose, pomalidomide was permanently discontinued. For daratumumab, there is no dose reduction, but delay in treatment until resolution of cytopenia and or infection.
Response to therapy was assessed using the International Myeloma Working Group (IMWG) criteria [12 (link)]. Grading of hematological and non-hematological adverse events was determined following the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [13 ]. Survival outcomes such as PFS and overall survival (OS) were estimated by means of Kaplan-Meier curves using log-rank testing.
Acetaminophen
Albuterol
Antiviral Agents
daratumumab
Dexamethasone
Diagnosis
Diphenhydramine
Disease Progression
Drug Tapering
Ethics Committees, Research
Gender
Glucocorticoids
Hyaluronidase
Infection
Innovativeness
Kidney
Lung Diseases
montelukast
Multiple Myeloma
Patients
pomalidomide
Therapeutics
Treatment Protocols
Youth
All available EMRs were searched to document the details of any type or combination of airway directed inhaled pharmacotherapy prescribed, more specifically—SABA (salbutamol); SAMA (ipratropium); LABA (formaterol, indacaterol, olodaterol, salmeterol, vilanterol); LAMA (aclidinium, glycopyronium, tiotropium, umeclidinium) and ICS (beclomethasone, budesonide, fluticasone). If the patients were identified to have been prescribed multiple/change in similar class of inhaled pharmacotherapy during the study period, the most recent/last prescribed type of therapy was included in the analysis. Patients inhaled pharmacotherapy use was defined as:
Albuterol
Beclomethasone
Budesonide
Fluticasone
indacaterol
Ipratropium
olodaterol
Patients
Pharmacotherapy
Salmeterol
Therapeutics
Tiotropium
umeclidinium
vilanterol
We recorded height in cm using a stadiometer. Trained technicians used the EasyOne (ndd Medizintechnik) spirometer to measure prebronchodilator and postbronchodilator (two puffs of salbutamol 100 µg)14 (link) lung function values, following established guidelines,15 (link) including FEV1 and forced vital capacity (FVC) in L, and their ratio (FEV1/FVC) in percentage. Spirometry was performed within respective textile mills during working hours. An improvement in FEV1 of ≥200 mL on postbronchodilator testing was considered as evidence of bronchodilator ‘response’ (BDR). We defined chronic airflow obstruction (CAO) as a postbronchodilator FEV1/FVC value below the lower limit of normality (LLN), derived from the third US National Health and Nutrition Examination Survey (NHANES-III; ‘Caucasian’) reference equations.16 (link)
Spirometry was undertaken on 1747 (86%) workers. During the COVID-19 pandemic, 216 workers were interviewed without spirometry; 6 employees had a contraindication to spirometry, 1 declined it and 61 were unable to perform the test. After the exclusion of a further 26 men who could not produce measurements of acceptable quality, a total of 1723 workers were included in the analyses of spirometry; they produced 1721 useable prebronchodilator and 1712 postbronchodilator measurements.
Spirometry was undertaken on 1747 (86%) workers. During the COVID-19 pandemic, 216 workers were interviewed without spirometry; 6 employees had a contraindication to spirometry, 1 declined it and 61 were unable to perform the test. After the exclusion of a further 26 men who could not produce measurements of acceptable quality, a total of 1723 workers were included in the analyses of spirometry; they produced 1721 useable prebronchodilator and 1712 postbronchodilator measurements.
Full text: Click here
Albuterol
Bronchodilator Agents
Caucasoid Races
Chronic Airflow Obstruction
Conditioning, Psychology
COVID 19
Forced Vital Capacity
Respiratory Physiology
Spirometry
Workers
We performed a single-center, prospective, observational cohort study of children between the ages of 6–17 years who were admitted to the Emory University-affiliated Children’s Healthcare of Atlanta 36-bed PICU for severe acute asthma between July 29, 2019, and February 10, 2021. The Emory University School of Medicine Institutional Review Board (IRB00110747) approved the study. Informed consent was obtained from all participants and/or their parent or legal guardian prior to enrollment. In accord with institutional requirements, we obtained verbal assent from children 6–10 years and written assent from children 11 years of age or greater prior to enrollment and any study procedures. All study procedures were performed according to the relevant guidelines and regulations in the Declaration of Helsinki. Children are admitted to the PICU for asthma if they received any of the following interventions in the Emergency Department: (1) a third continuous nebulized albuterol treatment, (2) non-invasive respiratory support delivered by high-flow nasal cannula or bilevel positive airway pressure, (3) intubation for invasive mechanical ventilation, (4) receipt of a 80%/20% helium–oxygen mixture for hypoxemia, or (5) required greater than or equal to 50% fraction of inspired oxygen by Venturi mask or positive pressure ventilation to maintain oxygen saturations ≥ 92%. Children were excluded if they had other chronic medical conditions requiring systemic corticosteroids or had disorders necessitating immunosuppressive medications such as a history of hematopoietic stem cell or solid organ transplant, oncologic diagnoses, sickle cell anemia, or rheumatologic diagnoses. Children with respiratory comorbidities such as cystic fibrosis, pulmonary aspiration, gastroesophageal reflux requiring acid suppression medication and/or tube-feed dependence, bronchiectasis, congenital airway anomalies, bronchopulmonary dysplasia, and/or a history of premature birth before 35-week gestation were excluded. Pregnant patients and those with a personal history of any recreational smoking or vaping were also excluded.
Full text: Click here
Adrenal Cortex Hormones
Albuterol
Anemia, Sickle Cell
Asthma
Biphasic Continuous Positive Airway Pressure
Bronchiectasis
Bronchopulmonary Dysplasia
Child
Children's Health
Chronic Condition
Congenital Abnormality
Cystic Fibrosis
Diagnosis
Ethics Committees, Research
Gastroesophageal Reflux Disease
Helium
Immunosuppressive Agents
Intermittent Positive-Pressure Ventilation
Intubation
Legal Guardians
Lung
Mechanical Ventilation
Nasal Cannula
Neoplasms
Organ Transplantation
Oxygen
Oxygen-20
Oxygen Saturation
Parent
Patients
Pharmaceutical Preparations
Pregnancy
Premature Birth
Respiratory Rate
Status Asthmaticus
Stem Cells, Hematopoietic
Top products related to «Albuterol»
Sourced in United States, United Kingdom, France
Salbutamol is a laboratory product manufactured by Merck Group. It is a bronchodilator medication used to treat asthma and other respiratory conditions. The core function of Salbutamol is to relax and open up the airways, making it easier to breathe.
Sourced in United Kingdom, Ireland
Ventolin is a handheld, portable medical device designed to administer medication for the treatment of respiratory conditions. It functions as an inhalation device to deliver bronchodilator medication directly to the lungs, providing relief for symptoms such as shortness of breath and wheezing.
Sourced in United States
The Vmax 22 is a laboratory equipment product manufactured by Cardinal Health. It is designed to perform various analytical tasks within a research or clinical laboratory setting. The core function of the Vmax 22 is to provide accurate and reliable measurements and analysis of samples. The specific capabilities and features of the Vmax 22 are not available in this factual and unbiased description.
Sourced in United States, Germany, United Kingdom, France, Sao Tome and Principe, Canada, Italy, Japan, China, Switzerland, Macao, Australia
Forskolin is a lab equipment product manufactured by Merck Group. It is a compound derived from the roots of the Coleus forskohlii plant. Forskolin is used as a tool for research purposes in the laboratory setting.
Sourced in Japan, United Kingdom
Salbutamol is a bronchodilator medication used to treat and prevent symptoms of asthma, COPD, and other respiratory conditions. It works by relaxing and opening the airways in the lungs, making it easier to breathe.
Sourced in United States
The Vmax 229 is a laboratory instrument designed for quantitative spectroscopic analysis. It provides precise measurements of absorbance, transmittance, and fluorescence in various sample types. The core function of the Vmax 229 is to perform accurate and reliable spectroscopic analyses in a variety of research and testing applications.
Sourced in United States, Germany, Japan, United Kingdom, Sao Tome and Principe, Canada, France, Denmark, Italy, Sweden
Isoproterenol is a synthetic catecholamine used as a laboratory reagent. It acts as a non-selective beta-adrenergic agonist, stimulating both beta-1 and beta-2 adrenergic receptors. Isoproterenol is commonly used in research applications to study cardiovascular and respiratory function.
Sourced in United States, Germany, United Kingdom, France, China, Italy, Canada
Norepinephrine is a laboratory product produced by Merck Group. It is a neurotransmitter and hormone that plays a role in the sympathetic nervous system. The core function of Norepinephrine is to regulate physiological processes such as heart rate, blood pressure, and pupil dilation.
Sourced in United States
Clenbuterol is a laboratory instrument used for various research and analytical applications. It is a high-precision device designed to perform accurate measurements and analyses. The core function of Clenbuterol is to provide reliable and consistent data to support scientific investigations.
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
More about "Albuterol"
Albuterol, a short-acting beta2-adrenergic agonist medication, is widely used to treat and prevent bronchospasm in patients with reversible obstructive airway diseases such as asthma.
Also known as Salbutamol or Ventolin, this inhalational drug works by relaxing and opening the airways, allowing for easier breathing.
Albuterol is available in various formulations, including metered-dose inhalers, nebulizer solutions, and oral tablets.
Careful dosing and monitoring are essential, as Albuterol can have stimulant effects and may interact with certain medications.
Researchers are actively studying the efficacy, safety, and optimal use of Albuterol, including exploring related compounds like Forskolin, Isoproterenol, Norepinephrine, and Clenbuterol.
PubCompare.ai, an AI-powered tool, can enhance Albuterol research by helping scientists locate the best protocols from literature, pre-prints, and patents, while ensuring reproducibility and accuracy.
By leveraging these advanced comparison tools, researchers can optimize their Albuterol studies and advance our understanding of this important respiratory medication.
Also known as Salbutamol or Ventolin, this inhalational drug works by relaxing and opening the airways, allowing for easier breathing.
Albuterol is available in various formulations, including metered-dose inhalers, nebulizer solutions, and oral tablets.
Careful dosing and monitoring are essential, as Albuterol can have stimulant effects and may interact with certain medications.
Researchers are actively studying the efficacy, safety, and optimal use of Albuterol, including exploring related compounds like Forskolin, Isoproterenol, Norepinephrine, and Clenbuterol.
PubCompare.ai, an AI-powered tool, can enhance Albuterol research by helping scientists locate the best protocols from literature, pre-prints, and patents, while ensuring reproducibility and accuracy.
By leveraging these advanced comparison tools, researchers can optimize their Albuterol studies and advance our understanding of this important respiratory medication.